JD Supra September 23, 2020
Healthcare artificial intelligence is a promising sector for PE investors that requires careful navigation, particularly given divergent regulatory approaches.
PE funds invested more than US$14 billion in healthcare (including pharma) in 2019, up from US$3.5 billion in 2013, and interest is likely to grow further, given the global impact of COVID-19. In our view, the application of artificial intelligence (AI) to healthcare and pharma is of increasing importance, and is likely to bring new deal opportunities for PE investors.
No longer an emergent technology, AI is now used to drive value and efficiency, including precision diagnosis, smart devices, clinical decision support, care orchestration, administration telehealth, and lifestyle improvements — and has also been shown to be capable of significantly reducing...